Skip to content
Media

The Rise of High-Tech, Needle-Free Facials: EMFACE® Surpasses One Million Treatments Globally

BTL Aesthetics Australia 2 mins read

The Rise of High-Tech, Needle-Free Facials: EMFACE® Surpasses One Million Treatments Globally

In an age where “natural results” and minimal downtime are top of mind, the beauty industry continues to innovate with non-invasive devices that aim to support facial structure and skin appearance—without the use of needles or surgery.

One such treatment leading this shift is EMFACE®, a device that has now been used in over one million treatments worldwide. Tapping into the growing demand for advanced skin and facial care, EMFACE is available in select clinics across Australia under the guidance of qualified healthcare professionals.

What Is EMFACE®?

EMFACE is a TGA-registered medical device (ARTG Identifiers 393998 and 394105) that combines High-Intensity Facial Electrical Stimulation (HIFES™) and Synchronized Radiofrequency (RF) in a single session. These technologies are intended to support:

  • Local muscle stimulation

  • Local tissue heating

  • Increased local blood circulation

  • Strengthening of facial muscles

  • Supporting the reduction of facial wrinkles and rhytids

Treatments are typically completed in approximately 20 minutes and involve no needles or surgical intervention. Individual experiences vary and treatment suitability must be assessed by a qualified practitioner.

A Focus on Natural-Looking Results

As the trend toward “tech facials” continues to grow, EMFACE reflects a broader industry move toward non-invasive, device-led treatments that focus on subtle yet noticeable results. With no injectables or downtime, the technology may appeal to those exploring preventative or maintenance-based aesthetic options under professional care.

The device’s new Eye Applicators—also included in its TGA registration—have been developed to support facial muscle stimulation around the eye area, giving practitioners additional tools to tailor treatments for individual facial regions.

Available at Leading Clinics

EMFACE is currently offered by a number of authorised Australian clinics, where treatments are customised by healthcare professionals based on individual needs and clinical judgement.

To learn more about EMFACE or find an authorised clinic:
🔗 btlaesthetics.com.au/for-providers/emface-providers


Media Enquiries
Simone Wyndham | Beauty PR Sydney
📧 [email protected]

Healthcare Professional Enquiries
Gareth Pepper | BTL Aesthetics Australia
📧 [email protected] | 📞 +61 (0) 435 769 639


Important Information:
• Always read the label and follow the directions for use.
• This product is not available for purchase by the general public and is intended for use by qualified healthcare professionals only.
• Consult a healthcare professional to determine if this treatment is appropriate for your needs.
• Patient experience and results may vary.


About us:

Founded in 1993, BTL Aesthetics is a leading innovator in non-invasive medical and aesthetic devices, with products including EMSCULPT NEO®, EXION™, EMSELLA®, and EXILIS ULTRA 360®. Operating in over 80 countries, BTL is committed to developing evidence-based technologies to support body contouring, facial rejuvenation, and intimate health.
🌐 Learn more: btlaesthetics.com.au

Media

More from this category

  • Community, Media
  • 10/06/2025
  • 10:08
Local & Independent News Association

LINA launches Newsroom Starter Kit to empower local communities to fill news deserts

Developed with grassroots publishers, journalists, and media experts, the Starter Kit responds to the urgent needs of communities left behind by the collapse of…

  • Contains:
  • Media, Medical Health Aged Care
  • 10/06/2025
  • 08:00
AstraZeneca

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR1 New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians. Australia could save $25.2 billion in CKD-related costs and more than halve dialysis demand over 25 years with early action.1 The model projects additional gains for the Australian economy and society with projections showing a $1.6 billion increase in net tax revenue could be achieved over the same period and 200,000 more people in the workforce.1 An estimated 2.7 million people in…

  • Contains:
  • Media
  • 01/06/2025
  • 06:41
AGENCE OLIVIA PAYERNE

ALL ENHANCES ITS ENTERTAINMENT OFFERING WITH INTERNATIONAL PARTNERSHIPS

FIRST PARTNERSHIP WITH OVO ARENA WEMBLEY IN ENGLAND RENEWED PARTNERSHIPS WITH MAJOR VENUES IN FRANCE, AUSTRALIA AND BRAZILSince 2019, music has been one of the three main areas of interest for members of ALL, Accor's booking platform and loyalty programme. ALL is strengthening its presence in the world of entertainment, offering unique and enriching experiences through partnerships with major venues, with benefits for members including meetings with artists, VIP box seats, and advance seating for the biggest concerts of the year.Meanwhile, gig-tripping, a trend combining travel with concert attendance, continues to grow. Travellers are organising their stays around major shows,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.